Zhengyang Yang, Jiale Gao, Jianyong Zheng, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Jie Zhang, Guangyong Chen, Rui Xu, Xiao Zhang, Yishan Liu, Zhigang Bai, Wei Deng, Wei He, Hongwei Yao, Zhongtao Zhang
Adding PD-1 blockade in the neoadjuvant regimens for locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) / mismatch repair-proficient (pMMR) tumors is an attractive, but debatable strategy. This phase 2, multicenter, prospective, single-arm study enrolled patients from 6 centers from June 2021 to November 2022. Locally advanced rectal cancer (LARC, cT3-4a N0 M0 and cT1-4a N1-2 M0 ) patients aged ≥18 years with the distance from distal border of tumor to anal verge ≤10 cm (identified by Magnetic Resonance Imaging) were qualified for inclusion...
March 11, 2024: Signal Transduction and Targeted Therapy